Skip to main navigation Skip to search Skip to main content

Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein

  • Ania M. Owsianka
  • , Alexander W. Tarr
  • , Zhen Yong Keck
  • , Ta Kai Li
  • , Jeroen Witteveldt
  • , Richard Adair
  • , Steven K.H. Foung
  • , Jonathan Ball
  • , Arvind H. Patel
  • University of Glasgow
  • University of Nottingham
  • Stanford University

Research output: Contribution to journalArticlepeer-review

134 Citations (Scopus)

Abstract

The humoral response to hepatitis C virus (HCV) may contribute to controlling infection. We previously isolated human monoclonal antibodies to conformational epitopes on the HCV E2 glycoprotein. Here, we report on their ability to inhibit infection by retroviral pseudoparticles incorporating a panel of full-length E1 E2 clones representing the full spectrum of genotypes 1-6. We identified one antibody, CBH-5, that was capable of neutralizing every genotype tested. It also potently inhibited chimeric cell culture-infectious HCV, which had genotype 2b envelope proteins in a genotype 2a (JFH-1) background. Analysis using a panel of alanine-substitution mutants of HCV E2 revealed that the epitope of CBH-5 includes amino acid residues that are required for binding of E2 to CD81, a cellular receptor essential for virus entry. This suggests that CBH-5 inhibits HCV infection by competing directly with CD81 for a binding site on E2.
Original languageEnglish
Pages (from-to)653-659
Number of pages7
JournalJournal of General Virology
Volume89
Issue number3
DOIs
Publication statusPublished - 1 Mar 2008
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein'. Together they form a unique fingerprint.

Cite this